U.S. District Court gives decision on Precedex® patent litigation
(Thomson Reuters ONE) -
Orion Corporation Stock Exchange Release 1 May 2012 at
16.00 EEST
Orion Corporation has received information that the United States District Court
for the District of New Jersey has rendered its decision on the patent
infringement lawsuit that Orion Corporation and Hospira Inc. filed on 4
September 2009 to enforce U.S. Patents Nos 4,910,214 and 6,716,867. The
respondents in the case are Sandoz Inc., Sandoz International GmbH and Sandoz
Canada Inc. (hereinafter collectively "Sandoz").
The court found that U.S. Patent No. 4,910,214 is valid and enforceable. Sandoz
is permanently enjoined from the commercial manufacture, use, sale or offer for
sale in the United States or importation into the United States of its generic
dexmedetomidine product until such time as U.S. Patent No. 4,910,214 expires,
including any applicable extensions. The Court also ordered that the effective
date of Sandoz' Abbreviated New Drug Application No. 91-465 shall not occur
until the expiration of the '214 patent, including any applicable extensions.
Separately, the court found that U.S. Patent No. 6,716,867 is invalid as
obvious.
Orion's partner Hospira Inc. sells Precedex® in the United States and in markets
outside Europe.
Orion is evaluating its further measures in the case. The company will announce
possible further information on the litigation in its upcoming Interim Reports
with the exception of final outcome of the litigation which will be published as
a stock exchange release.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO Senior VP, Corporate Functions
Contact person:
Olli Huotari, Senior VP, Corporate Functions, phone +358 10 426 3054, mobile
+358 50 966 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler(®) pulmonary drugs.
Orion's net sales in 2011 amounted to EUR 918 million and the company had about
3,400 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1607301]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.05.2012 - 09:01 Uhr
Sprache: Deutsch
News-ID 1109082
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Espoo
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 66 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"U.S. District Court gives decision on Precedex® patent litigation
"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
